SCLX vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 12, 2026
SCLX
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | SCLX | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 5.5772 | 10.1729 | SCLX |
| PEG Ratio | 0 | 6.565 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -22.8% | 4.0% | GSK |
| Earnings Growth | 0.0% | -22.8% | SCLX |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 52.0/100 | 40.8/100 | SCLX |
| Profit Margin | 0.0% | 13.0% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
SCLX
MarkdownPrice below a falling SMA50 (slope -31.2%), weak momentum, RSI 15
GSK
NeutralMixed signals - no dominant trend phase, RSI 54
Fundamentals Snapshot
| Metric | SCLX | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 2.2 | 10.2 |
| Trailing P/E | — | 17.9 |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.2% | 0.0% |
| Gross Margin | 0.6% | 0.7% |
| Operating Margin | -3.9% | 0.3% |
| EPS | -49.70 | 2.87 |
| Dividend Yield | — | 0.04% |